Academic Journal
Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society.
| Title: | Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. |
|---|---|
| Authors: | Sánchez-Prieto M; Department of Obstetrics and Gynecology, Dexeus Mujer, Hospital Universitario General de Catalunya, Sant Cugat del Vallès, Spain. Electronic address: mansan@dexeus.com., Romero-Domínguez M; Department of Obstetrics and Gynecology, Hospital QuironSalud Málaga, Málaga, Spain., Orozco R; Department of Obstetrics and Gynecology, Hospital QuironSalud Málaga, Málaga, Spain., Lilue M; Palacios Institute of Women's Health, Madrid, Spain., Lubián-López DM; Maternal and Child Health and Radiology, Faculty of Medicine, University of Cádiz, Cádiz, Spain., González SP; Menoclínica, Alfonso X el Sabio University, Madrid, Spain., Nieto A; Department of Obstetrics and Gynecology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Coronado P; Women's Health Institute, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Complutense University of Madrid, Madrid, Spain., Sánchez-Borrego R; DIATROS, Clínica de Atención a la Mujer, Barcelona, Spain., Cano A; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain., Castelo-Branco C; Department of Gynecology, Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain., Palacios S; Palacios Institute of Women's Health, Madrid, Spain. |
| Corporate Authors: | Young Investigators Group of the Spanish Menopause Society (MenoYoung Spain) |
| Source: | Maturitas [Maturitas] 2026 Oct; Vol. 213, pp. 109101. Date of Electronic Publication: 2026 Aug 25. |
| Publication Type: | Journal Article; Review; Consensus Statement |
| Language: | English |
| Journal Info: | Publisher: Elsevier/North Holland Biomedical Press Country of Publication: Ireland NLM ID: 7807333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4111 (Electronic) Linking ISSN: 03785122 NLM ISO Abbreviation: Maturitas Subsets: MEDLINE |
| Imprint Name(s): | Publication: Limerick : Elsevier/North Holland Biomedical Press Original Publication: Amsterdam, Elsevier/North Holland Biomedical Press. |
| MeSH Terms: | Obesity*/drug therapy , Incretins*/therapeutic use , Postmenopause* , Menopause*, Glucagon-Like Peptides/therapeutic use ; Humans ; Female ; Semaglutide ; Tirzepatide ; Spain ; Middle Aged ; Glucagon-Like Peptide-1 Receptor Agonists ; Weight Loss ; Estrogen Replacement Therapy |
| Abstract: | This position statement provides a focused framework for integrating incretin-based therapies into the care of peri- and postmenopausal women with overweight or obesity, with emphasis on body composition, cardiometabolic risk, musculoskeletal health, monitoring, and menopause hormone therapy. MenoYoung Spain, the Young Investigators Group of the Spanish Menopause Society, coordinated a structured literature review and iterative expert review process with senior Spanish Menopause Society experts. MEDLINE, Embase, and the Cochrane Library were searched through April 30, 2026 for studies evaluating glucagon-like peptide-1 receptor agonists and dual incretin therapies in peri- or postmenopausal women, menopause-stratified populations, and clinically relevant broader obesity populations. Evidence was synthesized narratively across predefined clinical domains, and 20 position statements were developed and reviewed by all authors. Semaglutide currently provides the largest amount of direct menopause-specific evidence among incretin-based therapies, although this evidence remains limited and largely observational. Tirzepatide and other dual incretin therapies are clinically promising, particularly for cardiometabolic disease and obstructive sleep apnea, but require menopause-specific evaluation. The association between concomitant use of menopause hormone therapy and greater semaglutide-related weight loss remains hypothesis-generating and should not justify initiating hormone therapy solely to augment weight loss. Incretin-based therapy in menopause should be considered within a cardiometabolic and functional framework that incorporates visceral adiposity, skeletal muscle health, fracture risk, cardiovascular prevention, individualized hormone therapy decision-making, resistance exercise, adequate protein intake, and structured monitoring of functional and metabolic outcomes. (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest All named authors completed the Elsevier declaration of competing interests form. Potential competing interests for named authors are reported in the submitted declaration file. Disclosures from members of the MenoYoung Spain Collaborative Group who are not named authors are provided in the Supplementary appendix. |
| Contributed Indexing: | Keywords: Body composition; Cardiometabolic health; Incretin-based therapy; Menopause; Menopause hormone therapy; Obesity |
| Substance Nomenclature: | 53AXN4NNHX (Semaglutide) 0 (Incretins) OYN3CCI6QE (Tirzepatide) 62340-29-8 (Glucagon-Like Peptides) 0 (Glucagon-Like Peptide-1 Receptor Agonists) |
| Entry Date(s): | Date Created: 20260828 Date Completed: 20260915 Latest Revision: 20260922 |
| Update Code: | 20260923 |
| DOI: | 10.1016/j.maturitas.2026.109101 |
| PMID: | 42664617 |
| Database: | MEDLINE |
| ISSN: | 1873-4111 |
|---|---|
| DOI: | 10.1016/j.maturitas.2026.109101 |